Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip
Aducanumab Added To 2021 Guidance Amid Approval Optimism
Biogen leans on aducanumab and other pipeline drugs as sales of Tecfidera and Spinraza slumped in Q4 and 2020. • Source: Shutterstock 
